NanoViricides, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NNVC research report →
Companywww.nanoviricides.com
NanoViricides, Inc. , a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide.
- CEO
- Anil R. Diwan
- IPO
- 2005
- Employees
- 7
- HQ
- Shelton, CT, US
Price Chart
Valuation
- Market Cap
- $28.95M
- P/E
- -4.33
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 424176.41
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -0.00%
- ROIC
- -0.00%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-9,466,966 · -14.14%
- EPS
- $-0.63 · 10.00%
- Op Income
- $-9,591,645
- FCF YoY
- -31.88%
Performance & Tape
- 52W High
- $2.23
- 52W Low
- $0.85
- 50D MA
- $1.21
- 200D MA
- $1.29
- Beta
- 1.54
- Avg Volume
- 298.99K
Get TickerSpark's AI analysis on NNVC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 21, 17 | BONIUK MILTON | other | 0 |
| Feb 21, 17 | Stephenson Fournier, PLLC | other | 0 |
| Aug 8, 22 | Diwan Anil | other | 94,471 |
| Feb 7, 20 | Jawadakar Makarand | other | 0 |
| Jun 2, 19 | Day Mark D. | other | 0 |
| May 21, 18 | BONIUK MILTON | other | 5,500,000 |
| Feb 21, 17 | BONIUK MILTON | other | 1,746,288 |
| Jul 11, 17 | BONIUK MILTON | other | 120,744 |
| May 4, 17 | BONIUK MILTON | other | 149,478 |
| Feb 21, 17 | BONIUK MILTON | other | 153,611 |
Our NNVC Coverage
We haven't published any research on NNVC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NNVC Report →